IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$80.39 USD
-0.45 (-0.56%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $80.43 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ITCI 80.39 -0.45(-0.56%)
Will ITCI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITCI
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Other News for ITCI
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Intra-Cellular price target raised by $6 at Needham, here's why
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Buy Rating Affirmed for Intra-Cellular Therapies with Caplyta Poised for Blockbuster Success